p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia

[1]  M. Cazzola,et al.  p53 lesions in leukemic transformation. , 2011, The New England journal of medicine.

[2]  K. Akashi,et al.  [Myeloid lineage commitment from the hematopoietic stem cell]. , 2007, Arerugi = [Allergy].

[3]  A. Fusco,et al.  from patients with acute myeloid leukemias 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts , 2011 .

[4]  M. Carroll,et al.  AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3 , 2010, Leukemia.

[5]  J. Maciejewski,et al.  Decitabine Maintains Hematopoietic Precursor Self-Renewal by Preventing Repression of Stem Cell Genes by a Differentiation-Inducing Stimulus , 2010, Molecular Cancer Therapeutics.

[6]  Helen Brady,et al.  A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines , 2010, PloS one.

[7]  Suman Lee,et al.  Undifferentiated hematopoietic cells are characterized by a genome-wide undermethylation dip around the transcription start site and a hierarchical epigenetic plasticity. , 2009, Blood.

[8]  R. Tuma.  Epigenetic therapies move into new territory, but how exactly do they work? , 2009, Journal of the National Cancer Institute.

[9]  H. Kantarjian,et al.  Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Perry,et al.  Chemical decomposition of 5-aza-2'-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. , 2009, Chemical research in toxicology.

[11]  Daniel Nowak,et al.  Differentiation therapy of leukemia: 3 decades of development. , 2009, Blood.

[12]  J. Downing,et al.  Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.

[13]  Michael Krauthammer,et al.  Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications , 2009, PloS one.

[14]  J. Dick,et al.  Stem cell concepts renew cancer research. , 2008, Blood.

[15]  Alexei Vazquez,et al.  The genetics of the p53 pathway, apoptosis and cancer therapy , 2008, Nature Reviews Drug Discovery.

[16]  G. Pruneri,et al.  Human acute leukemia cells injected in NOD/LtSz‐scid/IL‐2Rγ null mice generate a faster and more efficient disease compared to other NOD/scid‐related strains , 2008, International journal of cancer.

[17]  J. Gribben,et al.  Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. , 2008, Blood.

[18]  Yi Zheng,et al.  Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. , 2008, Cancer cell.

[19]  J. Herman,et al.  p21WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damage , 2008, Oncogene.

[20]  Heidi Dvinge,et al.  Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. , 2008, Cancer cell.

[21]  G. Mufti,et al.  CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine , 2007, Leukemia.

[22]  Jae K. Lee,et al.  A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery , 2007, Proceedings of the National Academy of Sciences.

[23]  H. Leonhardt,et al.  Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation , 2007, Nucleic acids research.

[24]  G. Schuurhuis,et al.  Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission , 2007, Leukemia.

[25]  W. Hofmann,et al.  The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia , 2007 .

[26]  N. Mahmud,et al.  Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. , 2007, Blood.

[27]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.

[28]  W. Hofmann,et al.  The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. , 2007, Blood.

[29]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[30]  T. Haferlach,et al.  Mutations of the TP53 Gene Occur in 13.4% of Acute Myeloid Leukemia and Are Strongly Associated with a Complex Aberrant Karyotype. , 2006 .

[31]  N. Sharpless,et al.  The Regulation of INK4/ARF in Cancer and Aging , 2006, Cell.

[32]  M. Cleary,et al.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. , 2006, Cancer cell.

[33]  S. Lowe,et al.  Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. , 2006, Experimental hematology.

[34]  M. Grever,et al.  Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. , 2006, Rapid communications in mass spectrometry : RCM.

[35]  M. Lübbert,et al.  Effects of 5-aza-2′-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells , 2006, Leukemia.

[36]  L. Donehower,et al.  Probing p53 biological functions through the use of genetically engineered mouse models. , 2005, Mutation research.

[37]  B. Dörken,et al.  5‐Aza‐2′‐deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53‐independent apoptosis in myeloid leukemia , 2005, International journal of cancer.

[38]  F. Nielsen,et al.  The transcriptional program of terminal granulocytic differentiation. , 2004, Blood.

[39]  K. Akashi,et al.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. , 2004, Cancer cell.

[40]  M. Tormo,et al.  CD34+ Cells from Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Normal Bone Marrow Display Different Apoptosis and Drug Resistance–Associated Phenotypes , 2004, Clinical Cancer Research.

[41]  F. Yamasaki,et al.  5‐azacytidine supports the long‐term repopulating activity of cord blood CD34+ cells , 2004, American journal of hematology.

[42]  N. Mahmud,et al.  Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. , 2004, Blood.

[43]  M. Bernstein,et al.  Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2'-deoxycytidine (Decitabine). , 2004, Anticancer research.

[44]  R. Hoffman,et al.  Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. , 2003, Blood.

[45]  C. Eaves,et al.  Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors , 2003, Leukemia.

[46]  D. Tenen,et al.  CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. , 2003, Blood.

[47]  T. Kamijo,et al.  Dynamic DNA methylation change in the CpG island region of p15 during human myeloid development. , 2001, The Journal of clinical investigation.

[48]  Y. Hayashi,et al.  Sensitization by 5‐aza‐2′‐deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all‐trans retinoic acid and 1α,25‐dihydroxyvitamin D3 , 2001, British journal of haematology.

[49]  J. Rowley,et al.  Cytogenetic and molecular analysis of the acute monocytic leukemia cell line THP‐1 with an MLL‐AF9 translocation , 2000, Genes, chromosomes & cancer.

[50]  L. Kelley,et al.  Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase. , 2000, Blood.

[51]  Y. Furukawa,et al.  Lineage‐specific regulation of cell cycle control gene expression during haematopoietic cell differentiation , 2000, British journal of haematology.

[52]  H. Sutherland,et al.  Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). , 2000, Experimental hematology.

[53]  T. Naoe,et al.  Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy , 1999, Leukemia.

[54]  Y. Saunthararajah,et al.  Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. , 1999, Cancer research.

[55]  C. Barlow,et al.  Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Lansdorp,et al.  Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. , 1997, Blood.

[57]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[58]  James M. Roberts,et al.  A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.

[59]  K. Manova-Todorova,et al.  Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.

[60]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[61]  B. Quesnel,et al.  p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.

[62]  J. Dick,et al.  Engraftment of immune-deficient mice with human hematopoietic stem cells. , 1988, Science.

[63]  K. Kohn,et al.  Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. , 1986, Cancer research.

[64]  A. Fusco,et al.  5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. , 1984, Blood.

[65]  J. Lotem,et al.  Cell differentiation and therapeutic effect of low doses of cytosine arabinoside in human myeloid leukemia. , 1984, Leukemia research.

[66]  J. Christman,et al.  Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. , 1982, The Journal of biological chemistry.

[67]  Kun-Tsan Lin,et al.  Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. , 1981, Leukemia research.

[68]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[69]  R. Momparler,et al.  In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine. , 1977, Cancer research.

[70]  F. Šorm,et al.  Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. , 1968, Neoplasma.

[71]  K. Kratochwil,et al.  Induction and differentiation of an epithelial tumour in the newt (Triturus cristatus). , 1962, Journal of embryology and experimental morphology.

[72]  G. B. Pierce,et al.  An in vitro and in vivo study of differentiation in teratocarcinomas , 1961, Cancer.